Targets › CD180
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2028.
Pattern recognition receptor predominantly expressed on B-cells, dendritic cells, and certain monocytes/macrophages, structurally resembling Toll-like receptors (TLRs) that plays a role in modulating immune responses. While ressembling a TLR, lacks the intracellular TIR (Toll/IL-1R) signaling domain and thus does not directly transduce signals. (UniProt, Q99467)
Open in Phaseline: the race on CD180, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | CD180 CART anti-CD180 CAR-T cell therapy | CD180 | Phase 1 | Acute Myeloid Leukemia | Jun 2028 |
Acute Myeloid Leukemia (1)
other (1)
Institute of Hematology & Blood Diseases Hospital, China (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.